Señales en vivo de 3737.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 21:20):

Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China...

Stats
Volumen de hoy	1 000.00
Volumen promedio	751 308
Capitalización de mercado	1.02B
EPS	HKD0 ( 2023-08-23 )
Próxima fecha de ganancias	( HKD0 ) 2024-05-17
Last Dividend	HKD0.0300 ( 2023-05-23 )
Next Dividend	HKD0 ( N/A )
P/E	5.71
ATR14	HKD0.0110 (0.92%)

Zhongzhi Pharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zhongzhi Pharmaceutical Finanzas

Annual	2023
Ingresos:	HKD2.05B
Beneficio Bruto:	HKD1.22B (59.43 %)
EPS:	HKD0.190

FY	2023
Ingresos:	HKD2.05B
Beneficio Bruto:	HKD1.22B (59.43 %)
EPS:	HKD0.190

FY	2022
Ingresos:	HKD1.83B
Beneficio Bruto:	HKD1.07B (58.45 %)
EPS:	HKD0.130

FY	2021
Ingresos:	HKD1.75B
Beneficio Bruto:	HKD1.06B (60.78 %)
EPS:	HKD0.0630

Financial Reports:

No articles found.

Zhongzhi Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0300 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Zhongzhi Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.95 - good (99.47%) | Divividend Growth Potential Score: 3.81 - Decrease likely (23.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0350	2016-05-17
Last Dividend	HKD0.0300	2023-05-23
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	HKD0.282	--
Avg. Dividend % Per Year	0.00%	--
Score	2.68	--
Div. Sustainability Score	9.95
Div.Growth Potential Score	3.81
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-11-25)

HKD0 Estimate 3.36 %

Dividend Stability

0.27 Very Poor

Dividend Score

2.68

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3302.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
1515.HK	Ex Dividend Junior	2023-06-07	Annually	0.00%
0560.HK	Ex Dividend Junior	2023-06-26	Annually	0.00%
8473.HK	Ex Dividend Knight	2023-08-15	Annually	0.00%
2020.HK	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
1093.HK	Ex Dividend Knight	2023-09-07	Annually	0.00%
0158.HK	Ex Dividend Junior	2023-06-15	Semi-Annually	0.00%
3759.HK	Ex Dividend Knight	2023-07-18	Annually	0.00%
1666.HK	Ex Dividend Knight	2023-06-19	Annually	0.00%
0700.HK	Ex Dividend Knight	2023-05-19	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0794	1.500	8.41	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0908	1.200	6.97	8.37	[0 - 0.3]
returnOnEquityTTM	0.154	1.500	9.40	10.00	[0.1 - 1]
payoutRatioTTM	0.714	-1.000	2.86	-2.86	[0 - 1]
currentRatioTTM	1.436	0.800	7.82	6.25	[1 - 3]
quickRatioTTM	0.813	0.800	9.93	7.94	[0.8 - 2.5]
cashRatioTTM	0.270	1.500	9.61	10.00	[0.2 - 2]
debtRatioTTM	0.126	-1.500	7.91	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.113	2.00	9.96	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0753	2.00	-0.0376	-0.0753	[0 - 20]
debtEquityRatioTTM	0.215	-1.500	9.14	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.593	1.000	3.46	3.46	[0.2 - 0.8]
operatingProfitMarginTTM	0.0800	1.000	-0.401	-0.401	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.451	1.000	8.61	8.61	[0.2 - 2]
assetTurnoverTTM	1.143	0.800	5.71	4.57	[0.5 - 2]
Total Score				9.95

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	6.06	1.000	9.49	0	[1 - 100]
returnOnEquityTTM	0.154	2.50	9.62	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0753	2.00	-0.0251	-0.0753	[0 - 30]
dividendYielPercentageTTM	8.89	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.113	2.00	9.96	10.00	[0 - 30]
payoutRatioTTM	0.714	1.500	2.86	-2.86	[0 - 1]
pegRatioTTM	0.0605	1.500	-2.93	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0495	1.000	-1.262	0	[0.1 - 0.5]
Total Score				3.81

Zhongzhi Pharmaceutical

Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also manufacture and sale of food and Chinese herbs; property management; and pharmaceutical drugs, as well as offers detection and testing services. As of December 31, 2021, it operated 398 self-operated chain pharmacies, including 361 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.